Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent to recover hematopoiesis function and its compositions and usage

A technology for hematopoietic function and composition, applied in the field of therapeutic agents, can solve the problems of reducing the effectiveness of toxic and side effects of the body's hematopoietic system, reducing the function of the body's bone marrow, and reducing the blood supply function, so as to reduce toxic reactions, reduce volume, and reduce toxic and side effects. Effect

Inactive Publication Date: 2005-01-19
QINGDAO KANGLITAI PHARMA
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

What's more, some treatment measures for diseases like tumors sometimes also lead to the reduction of the body's blood supply function and / or the reduction of the body's bone marrow function
Toxic side effects of these treatments on the body's hematopoietic system greatly reduce their effectiveness and lead to the necessity of cessation of these treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent to recover hematopoiesis function and its compositions and usage
  • Therapeutic agent to recover hematopoiesis function and its compositions and usage
  • Therapeutic agent to recover hematopoiesis function and its compositions and usage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0165] The 19 protein factors were divided into six groups and given to experimental animals. According to the understanding of the functions of these 19 protein factors, they were divided into six groups from A to F, as listed in Table 3. Each group of protein factors has similar or related functions of the same protein family. In experimental groups #2 to #7, protein combinations A to F were removed from the 19 protein factors to observe the recovery of the hematopoietic system by the corresponding protein combinations. The experimental results are summarized in Table 3.

[0166] table 3

[0167] In this experiment, one injection was administered, with 5 mice in each group. #8 is the control group, injected with phosphate buffered saline (PBS)

[0168] A FGF-1

[0169] Survival rate (%) 80 20 0 40 0 ​​60 60 40

Embodiment 2

[0171] In this experiment, the mice were irradiated twice, 3 hours apart, 500 Rad each time. A single protein factor / formulation or a composition containing a single protein factor or a single protein factor plus serum was injected into mice once through the tail vein. Unless otherwise specified, the two administration time points are generally 30 to 60 minutes and 12 hours after the second radiation or 24 hours and 12 hours before the first radiation. The experimental results are summarized in figure 1 .

[0172] In Table 4 below, "after administration" means administering the composition 30 minutes and 12 hours after the second radiation; "after 30 minutes and 12 hours", "after 6 hours and 18 hours", "12 hours and After 24 hours", "after 24 hours and 36 hours" refers to administering the composition at a given time point after the second radiation; "24 hours and 12 hours before radiation" refers to 24 hours before the first radiation and administer the pharmaceutical comp...

Embodiment 3

[0176] Histological studies were performed to show differences between control and experimental animals. In this experiment, 24 hours and 12 hours before the experimental mice received the second ionizing radiation radiation, IL-12 was injected into the tail vein of the mice respectively, with a dose of 100 ng per mouse each time, and mice in the control group were injected with Phosphate buffered saline (PBS buffer). After the injection, the mice in the control group and the experimental group received radiation radiation twice at the same time, with an interval of 3 hours in between, and each radiation dose was 500RAD. On the 1st and 7th day after radiation, the hind femurs were removed from the mice in the control combination experimental group, and fixed in 10% formalin for 24 hours for tissue sectioning and hematoxylin and eosin (H&E )dyeing. from figure 2 It can be seen that, compared with the control group, the protective effect of IL-12 on the bone marrow was clear...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a therapeutic agent, composition and method for promoting restoration of hematopoiesis function, in particular to a hematopoiesis promoting therapeutic agent, composition and method for resisting toxic and side effect of radiotherapy and chemotherapy. The optical execution mode of the invention comprises a pharmaceutical composition contained IL-12 or pharmaceutical composition comprising at least two of the following protein factor: CSF-1,EGF,IGF-1,TNF-alpha,VEGF,MIP-1,IL-1,IL-6,FGF-1,FGF-2,FGF-7,PDGF,TGF-beta1,TGF-beta2,TGF-alpha,ANG-1,MCP-1,PF-4 or IL-8 The pharmaceutical composition can be administered before, in and after the basic therapy process like radiotherapy and / or chemotherapy.

Description

Background technique [0001] Many diseases are caused by the loss of hematopoiesis throughout the body, or the deficiency of one or more blood cell lines in the blood. Disorders of certain blood cell lines in the body's hematopoietic system can also cause some diseases, such as leukemia. What's more, some treatment measures for diseases like tumors sometimes also lead to the reduction of the body's blood supply function and / or the decline of the body's bone marrow function. The toxic side effects of these treatments on the body's hematopoietic system greatly reduce their effectiveness and can lead to the necessity of cessation of these treatments. [0002] Therefore, there is an urgent need to develop a treatment method that can restore the body's hematopoietic function as an adjuvant treatment method for basic treatment [such as radiotherapy and / or chemotherapy]. These adjuvant therapies maintain, stimulate and / or regulate the patient's blood supply to compensate for the tox...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/20A61P7/00A61P35/00
Inventor 威廉·法兰西·安德森陈廷超赵毅
Owner QINGDAO KANGLITAI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com